Phix Pharma

Phix Pharma is a biotechnology company focused on the discovery and development of small molecule therapeutics that target RNA to treat genetic diseases. A spin-out from the University of Oxford and the MRC Laboratory of Molecular Biology, the company leverages a proprietary platform to identify small molecules capable of binding to specific RNA structures and sequences. Its lead programs are directed toward repeat expansion diseases, with a primary focus on myotonic dystrophy type 1 (DM1). By targeting the underlying RNA pathology, Phix Pharma aims to provide disease-modifying treatments for conditions that currently have limited therapeutic options.